Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait.
Identifieur interne : 001E06 ( Ncbi/Merge ); précédent : 001E05; suivant : 001E07Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait.
Auteurs : Chul Hyoung Lyoo [Corée du Sud] ; Sargo Aalto ; Juha O. Rinne ; Ki Ook Lee ; Seung Hun Oh ; Jin Woo Chang ; Myung Sik LeeSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Brain Mapping, Cerebral Cortex (cytology), Cerebral Cortex (physiology), Cerebral Cortex (radionuclide imaging), Combined Modality Therapy, Deep Brain Stimulation, Female, Fluorodeoxyglucose F18 (diagnostic use), Gait Disorders, Neurologic (drug therapy), Gait Disorders, Neurologic (physiopathology), Gait Disorders, Neurologic (radionuclide imaging), Humans, Levodopa (therapeutic use), Male, Middle Aged, Neural Pathways, Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (physiopathology), Parkinsonian Disorders (radionuclide imaging), Positron-Emission Tomography, Radiopharmaceuticals (diagnostic use), Subthalamic Nucleus (cytology), Subthalamic Nucleus (physiology), Subthalamic Nucleus (radionuclide imaging).
- MESH :
- chemical , diagnostic use : Fluorodeoxyglucose F18, Radiopharmaceuticals.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- cytology : Cerebral Cortex, Subthalamic Nucleus.
- drug therapy : Gait Disorders, Neurologic, Parkinsonian Disorders.
- physiology : Cerebral Cortex, Subthalamic Nucleus.
- physiopathology : Gait Disorders, Neurologic, Parkinsonian Disorders.
- radionuclide imaging : Cerebral Cortex, Gait Disorders, Neurologic, Parkinsonian Disorders, Subthalamic Nucleus.
- Adult, Aged, Brain Mapping, Combined Modality Therapy, Deep Brain Stimulation, Female, Humans, Male, Middle Aged, Neural Pathways, Positron-Emission Tomography.
Abstract
Inconsistent response in freezing of gait (FOG) with levodopa treatment or STN DBS makes the pathogenesis difficult to understand. We studied brain areas associated with the expression of STN DBS effect on parkinsonian motor deficits and FOG. Ten Parkinson's disease patients with typical FOG were included. One month before STN DBS, we performed [(18)F]-deoxyglucose PET scans and measured the UPDRS motor and modified FOG (mFOG) scores during levodopa off and on periods. At two months after STN DBS, same rating scores were measured. The percentage improvement of mFOG and UPDRS motor scores by STN DBS during levodopa off period was calculated. We searched for brain areas in which glucose metabolism correlated with the improvement of mFOG and UPDRS motor scores by DBS. During levodopa off period, STN DBS improved the UPDRS motor scores by 32.3% and the mFOG scores by 56.6%. There was no correlation between the improvements of both scores. The improvement of UPDRS motor score by DBS correlated with the metabolic activities of rostral supplementary motor area (Brodmann's area 8; BA8), anterior cingulate cortex (BA32), and prefrontal cortex (BA9). On the other hand, there was a positive correlation between the improvement of mFOG score by DBS and the metabolic activity of the parietal, occipital, and temporal sensory association cortices. In conclusion, dysfunction of different cerebral cortical areas limits the beneficial effects of DBS on parkinsonian motor deficits and FOG.
DOI: 10.1002/mds.21609
PubMed: 17712844
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002553
- to stream PubMed, to step Curation: 002553
- to stream PubMed, to step Checkpoint: 002867
Links to Exploration step
pubmed:17712844Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait.</title><author><name sortKey="Lyoo, Chul Hyoung" sort="Lyoo, Chul Hyoung" uniqKey="Lyoo C" first="Chul Hyoung" last="Lyoo">Chul Hyoung Lyoo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Youngdong Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Neurology, Youngdong Severance Hospital, Yonsei University College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Aalto, Sargo" sort="Aalto, Sargo" uniqKey="Aalto S" first="Sargo" last="Aalto">Sargo Aalto</name></author><author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O" last="Rinne">Juha O. Rinne</name></author><author><name sortKey="Lee, Ki Ook" sort="Lee, Ki Ook" uniqKey="Lee K" first="Ki Ook" last="Lee">Ki Ook Lee</name></author><author><name sortKey="Oh, Seung Hun" sort="Oh, Seung Hun" uniqKey="Oh S" first="Seung Hun" last="Oh">Seung Hun Oh</name></author><author><name sortKey="Chang, Jin Woo" sort="Chang, Jin Woo" uniqKey="Chang J" first="Jin Woo" last="Chang">Jin Woo Chang</name></author><author><name sortKey="Lee, Myung Sik" sort="Lee, Myung Sik" uniqKey="Lee M" first="Myung Sik" last="Lee">Myung Sik Lee</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21609</idno><idno type="RBID">pubmed:17712844</idno><idno type="pmid">17712844</idno><idno type="wicri:Area/PubMed/Corpus">002553</idno><idno type="wicri:Area/PubMed/Curation">002553</idno><idno type="wicri:Area/PubMed/Checkpoint">002867</idno><idno type="wicri:Area/Ncbi/Merge">001E06</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait.</title><author><name sortKey="Lyoo, Chul Hyoung" sort="Lyoo, Chul Hyoung" uniqKey="Lyoo C" first="Chul Hyoung" last="Lyoo">Chul Hyoung Lyoo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Youngdong Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Neurology, Youngdong Severance Hospital, Yonsei University College of Medicine, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Aalto, Sargo" sort="Aalto, Sargo" uniqKey="Aalto S" first="Sargo" last="Aalto">Sargo Aalto</name></author><author><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O" last="Rinne">Juha O. Rinne</name></author><author><name sortKey="Lee, Ki Ook" sort="Lee, Ki Ook" uniqKey="Lee K" first="Ki Ook" last="Lee">Ki Ook Lee</name></author><author><name sortKey="Oh, Seung Hun" sort="Oh, Seung Hun" uniqKey="Oh S" first="Seung Hun" last="Oh">Seung Hun Oh</name></author><author><name sortKey="Chang, Jin Woo" sort="Chang, Jin Woo" uniqKey="Chang J" first="Jin Woo" last="Chang">Jin Woo Chang</name></author><author><name sortKey="Lee, Myung Sik" sort="Lee, Myung Sik" uniqKey="Lee M" first="Myung Sik" last="Lee">Myung Sik Lee</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Brain Mapping</term><term>Cerebral Cortex (cytology)</term><term>Cerebral Cortex (physiology)</term><term>Cerebral Cortex (radionuclide imaging)</term><term>Combined Modality Therapy</term><term>Deep Brain Stimulation</term><term>Female</term><term>Fluorodeoxyglucose F18 (diagnostic use)</term><term>Gait Disorders, Neurologic (drug therapy)</term><term>Gait Disorders, Neurologic (physiopathology)</term><term>Gait Disorders, Neurologic (radionuclide imaging)</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neural Pathways</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (physiopathology)</term><term>Parkinsonian Disorders (radionuclide imaging)</term><term>Positron-Emission Tomography</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Subthalamic Nucleus (cytology)</term><term>Subthalamic Nucleus (physiology)</term><term>Subthalamic Nucleus (radionuclide imaging)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Fluorodeoxyglucose F18</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Cerebral Cortex</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gait Disorders, Neurologic</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Cerebral Cortex</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Gait Disorders, Neurologic</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Cerebral Cortex</term><term>Gait Disorders, Neurologic</term><term>Parkinsonian Disorders</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Brain Mapping</term><term>Combined Modality Therapy</term><term>Deep Brain Stimulation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neural Pathways</term><term>Positron-Emission Tomography</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Inconsistent response in freezing of gait (FOG) with levodopa treatment or STN DBS makes the pathogenesis difficult to understand. We studied brain areas associated with the expression of STN DBS effect on parkinsonian motor deficits and FOG. Ten Parkinson's disease patients with typical FOG were included. One month before STN DBS, we performed [(18)F]-deoxyglucose PET scans and measured the UPDRS motor and modified FOG (mFOG) scores during levodopa off and on periods. At two months after STN DBS, same rating scores were measured. The percentage improvement of mFOG and UPDRS motor scores by STN DBS during levodopa off period was calculated. We searched for brain areas in which glucose metabolism correlated with the improvement of mFOG and UPDRS motor scores by DBS. During levodopa off period, STN DBS improved the UPDRS motor scores by 32.3% and the mFOG scores by 56.6%. There was no correlation between the improvements of both scores. The improvement of UPDRS motor score by DBS correlated with the metabolic activities of rostral supplementary motor area (Brodmann's area 8; BA8), anterior cingulate cortex (BA32), and prefrontal cortex (BA9). On the other hand, there was a positive correlation between the improvement of mFOG score by DBS and the metabolic activity of the parietal, occipital, and temporal sensory association cortices. In conclusion, dysfunction of different cerebral cortical areas limits the beneficial effects of DBS on parkinsonian motor deficits and FOG.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17712844</PMID><DateCreated><Year>2007</Year><Month>12</Month><Day>06</Day></DateCreated><DateCompleted><Year>2008</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>15</Issue><PubDate><Year>2007</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait.</ArticleTitle><Pagination><MedlinePgn>2176-82</MedlinePgn></Pagination><Abstract><AbstractText>Inconsistent response in freezing of gait (FOG) with levodopa treatment or STN DBS makes the pathogenesis difficult to understand. We studied brain areas associated with the expression of STN DBS effect on parkinsonian motor deficits and FOG. Ten Parkinson's disease patients with typical FOG were included. One month before STN DBS, we performed [(18)F]-deoxyglucose PET scans and measured the UPDRS motor and modified FOG (mFOG) scores during levodopa off and on periods. At two months after STN DBS, same rating scores were measured. The percentage improvement of mFOG and UPDRS motor scores by STN DBS during levodopa off period was calculated. We searched for brain areas in which glucose metabolism correlated with the improvement of mFOG and UPDRS motor scores by DBS. During levodopa off period, STN DBS improved the UPDRS motor scores by 32.3% and the mFOG scores by 56.6%. There was no correlation between the improvements of both scores. The improvement of UPDRS motor score by DBS correlated with the metabolic activities of rostral supplementary motor area (Brodmann's area 8; BA8), anterior cingulate cortex (BA32), and prefrontal cortex (BA9). On the other hand, there was a positive correlation between the improvement of mFOG score by DBS and the metabolic activity of the parietal, occipital, and temporal sensory association cortices. In conclusion, dysfunction of different cerebral cortical areas limits the beneficial effects of DBS on parkinsonian motor deficits and FOG.</AbstractText><CopyrightInformation>(c) 2007 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyoo</LastName><ForeName>Chul Hyoung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Youngdong Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aalto</LastName><ForeName>Sargo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rinne</LastName><ForeName>Juha O</ForeName><Initials>JO</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ki Ook</ForeName><Initials>KO</Initials></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Seung Hun</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jin Woo</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Myung Sik</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D001931">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002540">Cerebral Cortex</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D046690">Deep Brain Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019788">Fluorodeoxyglucose F18</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020233">Gait Disorders, Neurologic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009434">Neural Pathways</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D049268">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020531">Subthalamic Nucleus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>2</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21609</ArticleId><ArticleId IdType="pubmed">17712844</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li></country><settlement><li>Séoul</li></settlement></list><tree><noCountry><name sortKey="Aalto, Sargo" sort="Aalto, Sargo" uniqKey="Aalto S" first="Sargo" last="Aalto">Sargo Aalto</name><name sortKey="Chang, Jin Woo" sort="Chang, Jin Woo" uniqKey="Chang J" first="Jin Woo" last="Chang">Jin Woo Chang</name><name sortKey="Lee, Ki Ook" sort="Lee, Ki Ook" uniqKey="Lee K" first="Ki Ook" last="Lee">Ki Ook Lee</name><name sortKey="Lee, Myung Sik" sort="Lee, Myung Sik" uniqKey="Lee M" first="Myung Sik" last="Lee">Myung Sik Lee</name><name sortKey="Oh, Seung Hun" sort="Oh, Seung Hun" uniqKey="Oh S" first="Seung Hun" last="Oh">Seung Hun Oh</name><name sortKey="Rinne, Juha O" sort="Rinne, Juha O" uniqKey="Rinne J" first="Juha O" last="Rinne">Juha O. Rinne</name></noCountry><country name="Corée du Sud"><noRegion><name sortKey="Lyoo, Chul Hyoung" sort="Lyoo, Chul Hyoung" uniqKey="Lyoo C" first="Chul Hyoung" last="Lyoo">Chul Hyoung Lyoo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E06 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001E06 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:17712844
|texte= Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:17712844" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |